Neuroprotection in progressive brain disorders

Israel Medical Association Journal

Volumn 5, Issue 8, 2003, Pages 576-580

  Djaldetti, Ruth ^a,b   Lev, Nirit ^a,b   Melamed, Eldad ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Degenerative diseases; Neuroprotection

Indexed keywords

ANTIOXIDANTS; BRAIN; DISEASE CONTROL;

BRAIN DISORDERS;

NEUROLOGY;

ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; CASPASE INHIBITOR; CATALASE; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN DERIVATIVE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; RASAGILINE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT SOMATOMEDIN C; REMACEMIDE; RILUZOLE; SELEGILINE; UBIDECARENONE; UNINDEXED DRUG; URATE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BRAIN DISEASE; CELL DEATH; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFECT; EXPERIMENTAL MODEL; FACTORIAL ANALYSIS; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW;

ANIMALS; APOPTOSIS; BRAIN DISEASES; CLINICAL TRIALS; EPIDEMIOLOGIC STUDIES; HUMANS; MICE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 0043067060     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Stefanis L, Burke RE, Greene LA. Apoptosis in neurodegenerative disorders. Curr Opin Neurol 1997;10:299-305.
2. Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-9.
3. Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999;399:263-7.
4. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-74.
5. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
6. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001;40:959-75.
7. Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49:561-74.
8. Strong MJ, Pattee GL. Creatine and coenzyme Q10 in the treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(Suppl 4):17-20.
9. Beal M.F. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 1999;9:261-6.
10. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
11. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
12. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
13. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18.
14. Bell JA, Beglan CL, London ED. Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Life Sci 1996;58:367-71.
15. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613-25.
16. Parkinson Studyn Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
17. Cochrane Database Syst Rev. Selegiline for Alzheimer's Disease. 2000;2:CD000442.
18. Rabey JM, Sagi I, Huberman M, et al. for the Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23:324-30.
19. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
20. Hunter C, Jankovic J. Double-blind, placebo-controlled study to assess safety and efficacy of riluzole as a neuroprotective drug in patients with early untreated Parkinson's disease. Neurology 1999;52(Suppl 2):214-15.
21. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999;14:326-30.
22. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001;54:329-38.
23. In 't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
24. Eisen A, Weber M. Treatment of amyotrophic lateral sclerosis. Drugs Aging 1999;14:173-96.
25. ALS CNTF treatment Study Group. A double-blind, placebo-controlled clinical trial of subcutaneous recombinant ciliary neurotrophic factor (RhCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-9.
26. Bilak MM, Kuncl RW. Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. Neuroreport 2001;12:2531-5.
27. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-6.
28. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
29. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-34.
30. Kordower JG, Emborg M, Bloch J, et al. Neurodegeneration prevented by Lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-73.
31. Genc S, Kuralay F, Genc K, et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated c57/BL mice via increasing nitric oxide production. Neurosci Lett 2001;298:139-41.
32. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-97.
33. Kessler II, Diamond EC. Epidemiological studies of Parkinson's disease. I: Smoking and Parkinson's disease: A survey and explanatory hypothesis. Am J Epidemiol 1971;94:16-25.
34. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 2000;283:2674-9.
35. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
36. Miller MM, Monjan AA, Buckholtz NS. Estrogen replacement therapy for the potential treatment or prevention of Alzheimer's disease. Ann N Y Acad Sci 2001;949:223-34.
37. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study. Mov Disord 2001;16:830-7.
38. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
39. Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002;58:S9-18.
40. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurology 2003;54:93-101.